CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Peripheral blood drawWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (10)

Name (Synonyms) Correlation
drug447 Duvelisib Wiki 0.71
drug1504 Zinc Wiki 0.41
drug685 Interferon Beta-1A Wiki 0.41
drug1476 Vitamin D Wiki 0.32
drug1475 Vitamin C Wiki 0.29
drug1172 Ruxolitinib Wiki 0.27
drug760 Lopinavir/ritonavir Wiki 0.21
drug1285 Standard of care Wiki 0.20
drug1146 Remdesivir Wiki 0.19
drug591 Hydroxychloroquine Wiki 0.15

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.08
D003141 Communicable Diseases NIH 0.07
D018352 Coronavirus Infections NIH 0.06
D007239 Infection NIH 0.05

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 A Pilot Study of Ruxolitinib to Combat COVID-19

The investigators hypothesize that JAK 1/2 inhibition with ruxolitinib, an FDA approved treatment for intermediate or high-risk myelofibrosis, could have a similar effect in patients with severe COVID-19, quelling the immune-hyperactivation, allowing for clearance of the virus and reversal of the disease manifestations.

NCT04354714 COVID-19 Drug: Ruxolitinib Procedure: Peripheral blood draw

Primary Outcomes

Measure: Overall survival

Time: Through 28 days

Secondary Outcomes

Measure: Length of hospital stay

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Length of ICU stay

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration of ventilator use

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration of vasopressors use

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration on renal replacement therapy

Time: Through completion of follow-up (estimated to be 7 months)

Description: -Defined as increase in viral load of >0.5 log on two consecutive days, or >1 log increase in one day, not in keeping with any baseline trend of rising viral loads during the pre-treatment viral testing

Measure: Viral kinetics as measured by virologic failure

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Number of adverse events as measured by CTCAE v. 5.0

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Proportion of participants with detectable virus

Time: Day 5

Measure: Proportion of participants with detectable virus

Time: Day 10

Measure: Proportion of participants with detectable virus

Time: Day 15

Measure: Proportion of participants with detectable virus

Time: Day 29

2 A Pilot Study of Duvelisib to Combat COVID-19

The exceedingly high mortality rates of severe and critical COVID-19 warrant the identification and evaluation of novel therapies that could potentially mitigate the advanced disease manifestations. Based on preclinical data from this institution and others, the investigators hypothesize that PI3K inhibition with duvelisib could potentially quell aberrant hyperactivtation of the innate immune system, preferentially polarize macrophages, reduce pulmonary inflammation, and limit viral persistence, thereby improving patient outcomes.

NCT04372602 COVID-19 Drug: Duvelisib Procedure: Peripheral blood draw

Primary Outcomes

Measure: Overall survival

Time: Through 28 days

Secondary Outcomes

Measure: Length of hospital stay

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Length of ICU stay

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration of ventilator use

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration of vasopressors use

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration on renal replacement therapy

Time: Through completion of follow-up (estimated to be 7 months)

Description: -Defined as increase in viral load of >0.5 log on two consecutive days, or >1 log increase in one day, not in keeping with any baseline trend of rising viral loads during the pre-treatment viral testing

Measure: Viral kinetics as measured by virologic failure

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Number of adverse events as measured by CTCAE v. 5.0

Time: Through completion of follow-up (estimated to be 7 months)

No related HPO nodes (Using clinical trials)